Although the cognitive and biological characteristics of Alzheimer’s disease (AD) are well known and mouse models of AD are available, current treatments for AD-related cognitive deficits have quite limited efficacy. The development of tasks with cross-species validity may enable better prediction of the efficacy of potential new treatments. In this issue of the
Kerin K. Higa, Jared W. Young, Mark A. Geyer